亚洲5亿人面临艾滋病感染的风险（图片来源：Flickr/世界银行图片库） 亚洲的科研机构启动了一个研究项目，从而开发专门适用于该地区的一种艾滋病疫苗。 亚洲艾滋病疫苗网络（AVAN）把来自澳大利亚、柬埔寨、中国、印度、印度尼西亚、日本、菲律宾、泰国、越南以及世界卫生组织的13所大学和科研机构的科研人员召集在一起。 去年在巴黎举行的2009艾滋病疫苗会议上宣布将建立AVAN。一个AVAN专家组已经建立起来，在中国设立了秘书处。最新一期的《公共科学图书馆—医学》杂志的一篇文章勾勒出了它的构想和目标。 “一个专门为了亚洲的疫苗研发计划有很多好处：例如，它将把重点放在一大批具有地区特异性的亚型和重组上，”澳大利亚国立艾滋病流行病学与临床研究中心主任、该网络的成员之一的David Cooper说。 他说，尽管该项目是全球应对艾滋病的举措的一部分，人们迫切需要一种针对亚洲的疫苗，亚洲有500万人被感染，5亿多人被认为面临感染风险。 AVAN的目标包括通过共享想法和共同工作从而协调成员之间的疫苗开发的举措，制定加速疫苗研发的地区策略，并拓展疫苗渠道。它的目标还包括提升临床试验和疫苗生产的能力，还打算实施伦理和管理框架。 Cooper说这项合作将发挥参与其中的科研机构和国家的力量，并改善能力建设以及该地区发达国家和发展中国家之间的技能转移。 例如，临床实验和伦理监管将大部分在泰国进行，去年在该国进行了迄今最有希望的艾滋病候选疫苗RV144的试验。培训网络成员将主要在澳大利亚、日本和泰国进行，而研究将在澳大利亚、中国、印度和马来西亚进行。 “我们将有能力汇集各国的专家技能，让他们取长补短，或者让具有互补需求的相邻国家研究组的实验室能力进行匹配，”Cooper说。 国际艾滋病疫苗项目的公共事务高级副主管Lisa Beyer说，AVAN将有助于推进设计一种可行的疫苗的举措，它受到了该领域的其它科研人员的广泛支持。 “开发一种艾滋病疫苗的举措是一种国际举措。不太可能提前知道未来开发出获得许可证的疫苗的科学进展将来自何方，但是这种举措肯定已经并且将继续因为亚洲科研人员的贡献而带来收益。”
At 10:50 on October 19, 2010 Source: Science Times
Asia's 500 million people face the risk of HIV infection (Source: Flickr / World Bank Photo Library)
Research institutions in Asia launched a research project to develop the region specifically for an AIDS vaccine. Asian AIDS Vaccine Network (AVAN) to come from Australia, Cambodia, China, India, Indonesia, Japan, Philippines, Thailand, Vietnam and the World Health Organization's 13 universities and research institutes bring together researchers. Held in Paris last year, AIDS vaccine conference in 2009 announced the establishment of AVAN. A AVAN Group has been established in China, set up a secretariat. The latest issue of "Public Library of Science - Medicine" magazine in an article outlining its vision and goals. "A special plan for vaccine development in Asia has many advantages: for example, it will focus on a large number of specific subtypes and recombinant region, the" Australian National HIV Epidemiology and Clinical Research Center, the network member of the David Cooper said. He said that although the global response to AIDS, the project is part of the initiative, it is an urgent need for a vaccine against the Asian, there are 500 million people are infected in Asia, 5 million people is considered to face the risk of infection. AVAN objectives, including through the sharing of ideas and work together in order to coordinate vaccine development among the members of the initiative to develop regional strategies to accelerate vaccine development and to expand the vaccine channels. It also aims to improve the clinical trials and vaccine production capacity, also intends to implement ethical and regulatory framework. Cooper said that this cooperation will play a part in scientific research institutions and national strength, and improve capacity building and the region between the developed and developing skills transfer. For example, clinical trials and ethical regulation will be mostly in Thailand, carried out in the country last year, by far the most promising experimental AIDS vaccine candidates RV144. Training members of the network will be mainly in Australia, Japan and Thailand, and study in Australia, China, India and Malaysia. "We will have the ability to bring together experts from various countries the skills to enable them to learn from each other, or adjacent to the complementary needs of the laboratory capacity of national research group match," Cooper said. International AIDS Vaccine Project senior vice president of public affairs, said Lisa Beyer, AVAN will help to promote the design of a viable vaccine initiatives, which by other researchers in the field of broad support. "Developing an AIDS vaccine initiative is an international initiative. Not likely to know in advance the future development of vaccines licensed scientific advances will come from, but this move certainly has and will continue because the contribution of scientific research personnel in Asia revenue. "
|
|
